How Nemifitide diTFA can Save You Time, Stress, and Money.
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze to evaluate several intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Primary demo targets were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patien